Piper Sandler lowered the firm’s price target on Cytek Biosciences to $8 from $8.50 and keeps an Overweight rating on the shares. The analyst updated models in the genomic tools and labs group following the Q2 earnings reports.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTKB:
- Cytek Biosciences narrows FY24 revenue view to $203M-$210M, consensus $208.8M
- Cytek Biosciences reports Q2 EPS (8c), consensus (3c)
- Cytek® Biosciences Automates Panel Design with New Intelligent Algorithm
- Cytek Biosciences to Report Second Quarter 2024 Financial Results on August 6, 2024
- Cytek Biosciences management to meet virtually with Piper Sandler